Related articles:

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
March 01, 2017
March 1, 2017

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
February 28, 2017
February 28, 2017

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
February 21, 2017
February 21, 2017

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
February 03, 2017
February 3, 2017

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
January 03, 2017
January 3, 2017

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4™ Study of Factor Xa Inhibitor Antidote AndexXa™ (andexanet alfa) in Patients with Acute Major Bleeding
August 30, 2016
August 30, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress
August 26, 2016
August 26, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)
August 17, 2016
August 17, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 09, 2016
August 9, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
August 02, 2016
August 2, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
May 27, 2016
May 27, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
May 23, 2016
May 23, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 05, 2016
May 5, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5
April 28, 2016
April 28, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan
April 04, 2016
April 4, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
February 26, 2016
February 26, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, February 26
February 19, 2016
February 19, 2016

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Monday, November 9
November 02, 2015
November 2, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors
September 24, 2015
September 24, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 04, 2015
August 4, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4
July 28, 2015
July 28, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief Commercial and Business Officer
June 15, 2015
June 15, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 06, 2015
May 6, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
May 05, 2015
May 5, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6
April 29, 2015
April 29, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Corporate Update
March 02, 2015
March 2, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2
February 24, 2015
February 24, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
February 09, 2015
February 9, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (FDA)
January 26, 2015
January 26, 2015

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
November 10, 2014
November 10, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Monday, November 10, 2014
November 03, 2014
November 3, 2014

Portola Pharmaceuticals Inc.: Portola Announces Pricing of Public Offering of Common Stock
October 02, 2014
October 2, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Announces Proposed Offering of Common Stock
October 01, 2014
October 1, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
August 06, 2014
August 6, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
July 30, 2014
July 30, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban
July 07, 2014
July 7, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
May 12, 2014
May 12, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
May 05, 2014
May 5, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
March 18, 2014
March 18, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
February 27, 2014
February 27, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
February 20, 2014
February 20, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)
February 03, 2014
February 3, 2014

Portola Pharmaceuticals Inc.: Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
January 13, 2014
January 13, 2014

Pin It on Pinterest

Share This